Mutational analysis of the Kir6.1 gene in Chinese hypertensive patients treated with the novel ATP-sensitive potassium channel opener iptakalim

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 757-760

  Duan, Ruifeng ^a   Cui, Wenyu ^a   Wang, Hai ^a,b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Thadweik Academy of Medicine   (China)

Author keywords

Hypertension; Iptakalim; Kir6.1 gene; Mutation

Indexed keywords

INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; IPTAKALIM;

ADULT; AGED; ARTICLE; CHINESE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL;

EID: 79958065605     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.259     Document Type: Article

References (23)

1. Zhang S, Mao G, Zhang Y, et al: Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension. Clin Ther 27: 1774-1784, 2005.
2. Trotta R, Donati MB and Iacoviello L: Trends in pharmacoge-nomics of drugs acting on hypertension. Pharmacol Res 49: 351-356, 2004.
3. Arnett DK and Claas SA: Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics 10: 1295-1307, 2009.
4. Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E and Arnett DK: Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. Stroke 42: 330-335, 2011.
5. Duarte JD, Lobmeyer MT, Wang Z, et al: Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics 20: 516-519, 2010.
6. Suonsyrjä T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K and Hiltunen TP: Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics 20: 342-345, 2010.
7. Nichols CG: KATP channels as molecular sensors of cellular metabolism. Nature 440: 470-476, 2006.
8. Wang H, Zhang YL and Chen YP: Targeting small arteries of hypertensive status with novel ATP-sensitive potassium channel openers. Curr Vasc Pharmacol 3: 119-124, 2005.
9. Wang H, Long CL and Zhang YL: A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. J Pharmacol Exp Ther 312: 1326-1333, 2005.
10. Gao S, Long CL, Wang RH and Wang H: KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res 83: 444-456, 2009.
11. Wang H, Tang Y, Wang L, Long CL and Zhang YL: ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives. Curr Med Chem 14: 133-155, 2007.
12. Chen YP, Qiu CR and Wang H: Cardiovascular pharmacological characterization of novel 2,3-dimethyl-2-butylamine derivatives in rats. Life Sci 75: 2131-2142, 2004.
13. Chen YP, Cui WY and Wang H: Selective actions of iptakalim on the subtypes of KATP channels. Chin Pharmacol Bull 22: 278-284, 2006.
14. Long CL, Qin XC, Pan ZY, et al: Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. J Hypertens 26: 2326-2338, 2008.
15. Duan RF, Cui WY, Gao HY, et al: Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population. Chin J Clin Pharmacol Ther 15: 961-966, 2010.
16. Evans WE and Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491, 1999.
17. Bettinaglio P, Galbusera A, Caprioli J, et al: Single strand conformation polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. Clin Biochem 35: 363-368, 2002.
18. Jun Lu, Shan Jiang, Song Ye and Chaopin Li: Detecting drug resistant genetic mutation among pneumoconiosis patients complicated with tuberculosis in Mycobacterium tuberculosis L-forms application of PCR-SSCP technique in Huainan mining district. J Nanjing Med Univ 3: 180-184, 2007.
19. Tomita H, Sasaki S, Osanai T, et al: Mutational analysis of Kir6.1 in Japanese patients with coronary spastic angina. Int J Mol Med 18: 589-591, 2006.
20. Emanuele E, Falcone C, Carabela M, et al: Absence of Kir6.1/ KCNJ8 mutations in Italian patients with abnormal coronary vasomotion. Int J Mol Med 12: 509-512, 2003.
21. Haïssaguerre M, Chatel S, Sacher F, et al: Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel. J Cardiovasc Electrophysiol 20: 93-98, 2009.
22. Kane GC, Lam CF, O'Cochlain F, et al: Gene knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal susceptibility to endotoxemia. FASEB J 20: 2271-2280, 2006.
23. Pan Z, Huang J, Cui W, Long C, Zhang Y and Wang H: Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol 56: 215-228, 2010.